STAT3 and Hepatic fibrosis: In summary, our current study not only indicates the IL-17A/STAT3 pathway playing a critical role in the pathogenesis of hepatic fibrosis, but also provides the proof of concept for this pathway acting as a potential therapeutic target against hepatic fibrosis.